Combining a premade SMN protein with a Spinraza-like drug (targets SMN2 gene) helped patient-derived motor neurons; potential ...
The Phase 3 STEER trial enrolled more than 100 children with SMA type 2, ages 2-17, who were able to sit, but hadn't walked ...